Roberta Zani

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients

Ezio Movilli, Giovanni Cancarini, Roberta Zani et al. · Nephrology Dialysis Transplantation · 2001 · 93 citations · Full text

Medicine, Hematology, Nephrology +17

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study

Luca Quartuccio, Francesca Zuliani, L. Corazza et al. · Journal of Autoimmunity · 2015 · 46 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC).

Massimo Galli, Letizia Oreni, Francesco Saccardo et al. · PubMed · 2017 · 43 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17